China SXT Pharmaceuticals Inc (SXTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has a cash flow conversion efficiency ratio of -0.032x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-494.08K) by net assets ($15.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
China SXT Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how China SXT Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SXTC total debt and obligations for a breakdown of total debt and financial obligations.
China SXT Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EverGen Infrastructure Corp
V:EVGN
|
-0.011x |
|
Mex Polska S.A.
WAR:MEX
|
0.244x |
|
Raj Oil Mills Limited
NSE:ROML
|
1.915x |
|
ZINC of Ireland NL
AU:ZMI
|
-0.016x |
|
JPMorgan European Growth & Income plc
LSE:JEGI
|
0.004x |
|
Entero Therapeutics, Inc.
NASDAQ:GRDX
|
-0.010x |
|
Immuron Ltd
AU:IMC
|
-0.189x |
|
Turbo Energy, S.A. American Depositary Shares
NASDAQ:TURB
|
-0.966x |
Annual Cash Flow Conversion Efficiency for China SXT Pharmaceuticals Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of China SXT Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $15.44 Million | $-2.35 Million | -0.152x | -9.75% |
| 2024-03-31 | $13.93 Million | $-1.93 Million | -0.138x | -2417.87% |
| 2023-03-31 | $14.69 Million | $-80.76K | -0.005x | -133.65% |
| 2022-03-31 | $16.42 Million | $268.29K | 0.016x | +119.80% |
| 2021-03-31 | $15.96 Million | $-1.32 Million | -0.082x | -183.00% |
| 2020-03-31 | $9.40 Million | $934.25K | 0.099x | +361.48% |
| 2019-03-31 | $11.11 Million | $239.19K | 0.022x | -96.32% |
| 2018-03-31 | $3.29 Million | $1.92 Million | 0.584x | +269.46% |
| 2017-03-31 | $1.85 Million | $293.04K | 0.158x | -35.61% |
| 2016-03-31 | $742.77K | $182.47K | 0.246x | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more